Objectives. To test the hypotheses that lidocaine 5% patches decrease the severity of acute pain and incidence of persistent incisional pain after robotic cardiac valve surgery.
Introduction
Post-thoracotomy pain is defined by persistent or recurrent incisional pain, or pain along an intercostal nerve cutaneous distribution, lasting at least 2 months [1] [2] [3] . It is reported in up to half of patients recovering from a thoracotomy, and is reported to be of moderate-tosevere intensity in most. Post-thoracotomy pain is more common than other persistent incisional pain, including post-sternotomy pain, postmastectomy pain, and postinguinal herniotomy pain. The pain is frequently associated with depression and insomnia [2] [3] [4] [5] [6] [7] [8] [9] .
Post-thoracotomy pain appears to be primarily neuropathic, characterized by shooting and burning sensations or numbness [6, 10, 11] . Persistent pain probably results from partial or complete intercostal nerve damage consequent to intraoperative mechanical trauma including nerve traction or compression, and occurs after both open and robotic procedures [12] . Persistent post-thoracotomy pain is notoriously difficult to treat; standard pain management techniques often fail, including opioids, anticonvulsants, and antidepressants [2, 4, [7] [8] [9] [12] [13] [14] .
Persistent post-thoracotomy pain is strongly associated with poor control of acute surgical pain. While association does not prove causality, it suggests that good control of acute pain may limit the progression to chronic pain [7, 9, 11, 12, [15] [16] [17] . A novel treatment for acute postoperative pain is topical lidocaine which can be provided in long-lasting patches. Topical lidocaine 5% patches interrupt pain signals from the fast sodium channels of neuronal membranes; topical lidocaine has limited systemic absorption and an excellent safety profile [18] . Lidocaine patches have been used in the treatment of a variety of neuropathic pain conditions including postherpetic neuralgia, post-thoracotomy pain, stump neuroma pain, intercostal neuralgia, diabetic polyneuropathy, meralgia paresthetica, complex regional pain syndrome, radiculopathy, postmastectomy pain, and various other focal peripheral neuropathic pain syndromes [1, [18] [19] [20] [21] [22] [23] [24] .
We, therefore, tested the primary hypothesis that 5% lidocaine patches reduce pain on postoperative days (POD) 7, 30, 90, and 180 after robotic cardiac surgery performed through a right-sided thoracotomy. Our secondary hypotheses were that 5% lidocaine patches reduces: 1) opiate use as measured in morphine sulfate equivalents and 2) acute pain through the first postoperative week measured by Visual Analog Scores (VAS) or Verbal Response Scores (VRS), and Global Perceived Effect (GPE), a measure of patient satisfaction.
Materials and Methods
With approval of the Institutional Review Board at Cleveland Clinic and written informed consent, we enrolled adults scheduled for robotic cardiac valve surgery.
Patients were excluded who had a history of severe psychiatric issues (e.g., depression, somatoform conversion disorder, and borderline personality disorder); who were addicted to alcohol, opioids, or illegal substances; had a known history of sensitivity to amide local anesthetics; had severe hepatic disease; or were pregnant.
Protocol
Robotic surgery was performed for mitral or aortic valve repair. Isolated left-lung ventilation was required for this procedure, and a thoracotomy was required to insert the surgical equipment into the chest cavity. The study was limited to surgeons who perform this procedure frequently. They used a similar approach to local anesthetic infiltration at the end of procedure. Intravenous ketamine was not used.
Patients were randomized 1:1, without stratification, to active lidocaine or identical-appearing placebo patches. Randomization was performed by our Research Pharmacy and was based on computer-generated codes. All investigators and clinicians were fully blinded to treatment. Active or identical-appearing placebo patches were applied in the intensive care unit to either side of the incision or around each incision circumferentially.
The 5% lidocaine transdermal patches (Lidoderm, Endo Pharmaceuticals, Malvern, PA) contained 700 mg of lidocaine. Each self-adhesive patch was 10 by 14 cm. Up to three patches were applied to maximize analgesia while reducing the risk of systemic toxicity. There is low systemic absorption of the lidocaine 5% patch, and approximately 95% of the lidocaine remains in the patch after 12 hours [25] . Patches were applied for 12 hours, removed for the subsequent 12 hours, and then new patches were applied. This process was continued for 6 months or until patients no longer required analgesia.
Additional postoperative analgesia was provided by patient-controlled fentanyl (20 mg bolus, 6-minute lockout, no hourly limit). Morphine or hydromorphone was substituted in patients reporting sensitivity to fentanyl. Patient-controlled analgesia was continued for up to 3 days, with the exception of a single patient who was treated for 5 days, until patients could tolerate oral opioid medications such as oxycodone 5-10 mg every 4-6 hours as needed. Patients who required more than 40 mg of oxycodone, or equivalent, per day were supplemented with fentanyl 25 mg/hour transdermal patches. Postoperative anti-inflammatory and nonopioid analgesic use was neither controlled nor measured.
Measurements
Incisional pain was evaluated over 6 months with data collected by an independent study coordinator who was blinded to treatment. A 100-mm Visual Analogue Score was first recorded the day before surgery, and then again on POD 3. On the second occasion, patients were asked to respond based on their average pain over the initial three POD, specifically at the site of the surgical incision. Subsequently, a VRS (with 0 indicating no pain and 10 indicating the worst imaginable pain) was determined by telephone after 1 week, 1 month, 3 months, and 6 months [26] [27] [28] . Given that postsurgical pain may be in part due to surgical positioning, endotracheal intubation, a prior chronic pain condition, or pain unrelated to the surgical procedure, we asked patients specifically about pain at their surgical sites. The Pain Disability Index (PDI) was determined in person the day before surgery, and then by telephone at the same intervals [29] .
The Depression Anxiety Stress Score was recorded once, the day before surgery [30] . GPE, a measure of patient satisfaction, was recorded by telephone after 1 week, 1 month, 3 months, and 6 months [31] . Opioids were converted to morphine sulfate equivalents (Table  A1) .
Data Analysis
Randomized groups were compared on potential baseline confounding variables using the standardized difference which is the difference in means or proportions divided by the pooled standard deviation. Any baseline variable with an absolute standardized difference of 0.46 or greater in absolute value was adjusted for in the analysis.
Our main analysis for the primary and secondary outcomes was modified intention-to-treat, in which we included all patients who received any part of the randomized intervention. For patients who had missing values of outcomes due to withdrawal or lost-to-followup, Table A2 shows how we replaced missing values (i.e., the last-observation carried-forward method). In addition to the modified intent-to-treat analyses, we performed an analysis using only the available data for each patient, again including all patients who received the intervention. Finally, for the primary outcome, we also performed a conservative intent-to-treat analysis using all randomized patients. In that analysis, we assigned the worst possible observed score to missing data points for those assigned to lidocaine 5% and the best possible observed score to missing data for placebo patients.
Repeated-measures analysis of variance was used to assess the relative treatment effect of lidocaine 5% patch compared to placebo on PDI score as well as VAS pain score. We assessed the effects of treatment, time, and the group-by-time interaction adjusting for the baseline scores respectively. For each outcome, if the Figure 1 CONSORT Flow Diagram. The modified intentto-treat population used for analysis included all patients who were randomized and received any of the study drug. Patients who were lost to follow-up had missing data imputed.
treatment-by-time interaction was statistically significant (P<0.10) we would assess the treatment effect at each time point using the Tukey-Kramer adjustment for multiple comparisons with correlated data. Otherwise, the main effect model was used to assess the effect of treatment. Treatment effect estimates were summarized using mean difference between groups with 95% confidence interval.
The relative treatment effect of lidocaine 5% patch compared to placebo on total opioid consumption was assessed using Wilcoxon rank sum test. A multivariable generalized estimating equation (GEE) logistic model was used to assess the relative treatment effect of lidocaine 5% patch versus placebo on each of the 3 questionnaires of GPE. We assessed the effects of treatment, time, and the group-by-time interaction, respectively. If the treatment-by-time interaction was not statistically significant (P0.10), the main effect model was used to access the effect of treatments. Treatment effect estimates were summarized using relative risk between groups with 95% confidence intervals.
Sample size was chosen to have 80% power at the 0.05 significance level to detect a difference of 6 points or more between groups on the primary outcome of PDI with a standard deviation of about 10.
The significance level was 0.05 for all tests. All analyses were performed with SAS 9.3 software (SAS Institute Inc., Cary, NC).
Results
A total of 80 patients were randomized between September 2009 and April 2011. Two patients were withdrawn because they had open-heart surgery instead of the originally scheduled robotic surgery. Analysis was therefore restricted to 39 patients randomized to lidocaine 5% patch and 39 patients randomized to placebo (Figure 1 ). Baseline characteristics of these patients are described in Table 1 . The lidocaine 5% patch and placebo groups were reasonably well balanced on available baseline variables (i.e., all standardized differences <0.46).
Mean PDI did not differ between the lidocaine 5% patch and placebo groups, with baseline-adjusted mean difference (95% CI) of 22.5 (27.11, 2.06), P 5 0.28, Table 2 .
There was no evidence that the treatment effect depended on time (group-by-time interaction P 5 0.58).
The estimated treatment effect (95% confidence interval) using the conservative intent-to-treat analysis described above reached the same conclusion, with baselineadjusted mean difference (95% CI) of 21.12 (23.95, 1.71), P 5 0.43.
No difference was found between the randomized groups on VAS pain score, with baseline-adjusted mean difference (95% CI) of 20.39 (21.04, 0.27), P 5 0.27, Table 3 . The treatment effect did not depend on time (group-by-time interaction P 5 0.68).
Lidocaine 5% patch (versus placebo) also did not affect opioid consumption during the initial 3 POD, with median difference (95%) IV morphine equivalent dose of 22. We found no effect of lidocaine 5% patch on any of the three GPE domains: pain (P 5 0.41), treatment efficacy (P 5 0.48), or patient satisfaction (P 5 0.17), Table 4 . The relative risk (95% CI) between the lidocaine 5% patch and placebo groups was 1.05 (0.94, 1.18) for less pain, 1.04 (0.94, 1.14) for treatment efficacy, and 1.04 (0.98, 1.10) for patient satisfaction.
Using an all-available-data approach instead of the modified intent-to-treat analyses above, all conclusions for primary and secondary outcomes remained unchanged.
Three lidocaine 5% patch patients (8%) and 3 placebo patients (8%) experienced an adverse event (chi-square P 5 0.95), Table A3 . None was attributed to the experimental treatment.
Discussion
Lidocaine 5% transdermal patches have been shown to be effective in the treatment of certain pain conditions such as postherpetic neuralgia and focal peripheral neuropathic pain syndromes [1, [18] [19] [20] [21] [22] [23] [24] . Lidocaine patches have also been shown to be effective in reducing postoperative pain as well, ranging from radical retropubic prostatectomy to laparoscopic herniotomy [19] . These factors prompted our investigation into the use of lidocaine patches to control post-thoracotomy pain: a potentially debilitating acute and chronic pain condition.
Lidocaine patches were expected to be helpful to treat post-thoracotomy pain, yet we found them to be ineffective in reducing acute and chronic pain after robotic cardiac valve surgery. For this reason, alternative analgesic measures should be chosen for patients undergoing this surgery.
Our negative results are consistent with studies showing no benefit of lidocaine patches in treating certain types of postoperative pain, such as in patients having undergone total knee arthroplasty [18] . Our patients may not have had notable relief in part because the intercostal nerves commonly affected by surgical thoracotomy lie between the ribs and well below the skin surface and thus not receiving the potential benefit of lidocaine absorption. Of note, studies including patients with traumatic rib fractures and lidocaine patches provide mixed results. In one study, lidocaine patches reduced pain in trauma patients with rib fractures [32] , while in another they did not significantly improve pain control in polytrauma patients with traumatic rib fractures [33] .
Other topical agents such as local anesthetics, antiinflammatories, anticonvulsants, central alpha agonists and N-methyl-D-aspartate (NMDA) receptor antagonists have been insufficiently studied for the prevention of post-thoracotomy pain. This includes diclofenac gel and the Eutectic Mixture of Local Anesthetic cream as well as creams compounded from ibuprofen, meloxicam, gabapentin, clonidine, and ketamine. Our results suggest that topical approaches with local anesthetic may not necessarily be effective for post-thoracotomy pain. It is unfortunate that lidocaine patches were not effective for this pain because other alternatives, including oral antidepressants, anticonvulsants, and opioid medications are suboptimal. All of these have systemic effects that may be substantial.
While the lidocaine patches can be deemed ineffective for our particular patient population, we note that baseline scores were low in both the lidocaine and placebo patch groups, particularly after 3 days. Perhaps consequently, and fortunately, our patient satisfaction was quite high. This may also be due to patients having a higher acceptance of postoperative pain of any sort after emergence from cardiac surgery, even though it was relatively minimally invasive. This being said, pain scores were lower than expected for an operation that had been thought to generate considerable postoperative pain.
Like postherniotomy pain, post-thoracotomy pain is thought to be related to both patient and surgical factors [34] . Minimally-invasive surgery, such as robotic valve surgery, likely produces less postoperative pain than surgeries involving larger thoracotomies. Additionally, considerable experience of the cardiac surgeons performing robotic cardiac valve surgery may have also contributed to the reduction in patient pain scores. Such surgeons aim to reduce the duration and the extent of rib retraction that may injure the intercostal nerves and contribute to post-thoracotomy pain. While clearly beneficial for the participating patients, low pain scores and low opioid use diminished our ability to detect benefit from the lidocaine patches.
Fortunately, few of our patients demonstrated persistent pain from robotic valve surgery. The incidence of persistent pain was similar in each group. Lidocaine patches failed to reduce persistent pain as measured by the PDI or the VAS. GPE-a measure of recovery and qualityof-life-also did not differ, possibly because patients were relieved to have had their major cardiac problem fixed as a result of this surgery.
Ours was a well-powered study with sufficient sample size. Baseline characteristics of the two subject groups were similar. Only two patients were eliminated from the analysis, as both eventually underwent open rather than robotic surgery. There were few missing values; consequently intention-to-treat and available-data analysis yielded similar results.
The amount of acute pain was low, as was the incidence of persistent pain. Our results should not be taken to mean that effective acute analgesia does not reduce the risk of persistent pain. In fact, whether effective acute analgesia prevents development of persistent incisional pain remains highly controversial, with some studies finding benefit [11, [15] [16] [17] 35] but others not [6] .
Few patients experienced complications, and the incidence was similar in both the lidocaine patch and placebo patch group. Furthermore, none of the complications appeared related to the lidocaine patches.
At least based on our sample of 78 patients, there was no indication that lidocaine patches augment risk.
Acute pain was evaluated in-hospital using conventional and well-validated instruments. Pain and quality-ofrecovery were subsequently evaluated by phone [26] [27] [28] . A single VAS score, in this case reflecting three postoperative dates of pain, is likely to have a degree of inaccuracy compared with more frequent measurements. Nonetheless, this provides a reasonably estimate of the extent to which patients are suffering pain.
We were unable to see patients and do more specific tests such as area-of-hyperalgesia after patient discharge. It remains possible that we missed subtle differences in persistent incisional pain. Given the low incidence and level of persistent pain, it seems highly unlikely that in-person evaluations would have substantially changed our conclusion that lidocaine patches do not reduce the risk or magnitude of persistent incisional pain after robotic cardiac surgery.
Robotic cardiac surgery was chosen as a model because it was thought to cause a moderate amount of pain that seemed likely to benefit from topical treatment. Our results could reasonably be extrapolated to operations with similar incisions, such as laparoscopic abdominal surgery. It remains possible that lidocaine patches will yet prove beneficial for smaller procedures involving minimal deep-tissue injury or larger procedures involving larger or open thoracotomies and more extensive rib retraction.
Conclusion
In summary, lidocaine 5% patches did not reduce acute or persistent pain in patients having robotic cardiac valve surgery, though pain scores were low in both treatment groups. Clinicians should choose alternative analgesic approaches for these patients.
Table A2
Withdrawal information and replaced values of missing outcomes for modified intent-to-treat analysis 
